Connect with us
[bsa_pro_ad_space id=12]

COVID-19

COVID Lab Leak: Over four later, EcoHealth Alliance funding is finally suspended

Published

12 months ago

8 minute read

From Heartland Daily News

Thursday, May 16, 2024

Federal Funding Stripped From Nonprofit at Center of COVID Lab Leak Controversy

Today, the Biden administration suspended federal funding to the scientific nonprofit whose research is at the center of credible theories that the COVID-19 pandemic was started via a lab leak at the Wuhan Institute of Virology.

This morning, the U.S. Department of Health and Human Services (HHS) announced that it was immediately suspending three grants provided to the New York-based nonprofit EcoHealth Alliance (EHA) as it starts the process of debarring the organization from receiving any federal funds.

“The immediate suspension of [EcoHealth Alliance] is necessary to protect the public interest and due to a cause of so serious or compelling a nature that it affects EHA’s present responsibility,” wrote HHS Deputy Secretary for Acquisitions Henrietta Brisbon in a memorandum signed this morning.

For years now, EcoHealth has generated immense controversy for its use of federal grant money to support gain-of-function research on bat coronaviruses at the Wuhan lab.

In a memo justifying its funding suspension, HHS said that EcoHealth had failed to properly monitor the work it was supporting at Wuhan. It also failed to properly report on the results of experiments showing that the hybrid viruses it was creating there had an improved ability to infect human cells.

Congressional Republicans leading an investigation into EcoHealth’s research in Wuhan, and the role it may have played in starting the pandemic via a lab leak, cheered HHS’s decision.

“EcoHealth facilitated gain-of-function research in Wuhan, China without proper oversight, willingly violated multiple requirements of its multimillion-dollar National Institutes of Health [NIH] grant, and apparently made false statements to the NIH,” said Rep. Brad Wenstrup (R–Ohio), chair of the House’s Select Subcommittee on the Coronavirus Pandemic in a statement. “These actions are wholly abhorrent, indefensible, and must be addressed with swift action.”

Beginning in 2014, EcoHealth received a grant from NIH’s National Institute of Allergies and Infectious Diseases (NIAID) to study bat coronavirus in China. Its initial scope of work involved collecting and cataloging viruses in the wild and studying them in the lab to spot which ones might be primed to “spillover” into humans and cause a pandemic.

Soon enough, EcoHealth used some of the viruses they’d collected to create “chimeric” or hybrid viruses that might be better able to infect human lung cells in genetically engineered (humanized) mice.

This so-called “gain-of-function” research has long been controversial for its potential to create deadly pandemic pathogens. In 2014, the Obama administration paused federal funding of gain-of-function research that might turn SARS, MERS, or flu viruses into more transmissible respiratory diseases in mammals.

In 2016, NIH flagged EcoHealth’s work as likely violating the 2014 pause.

EcoHealth President Peter Daszak argued to NIH at the time that the viruses his outfit was creating had not been proven to infect human cells and were genetically different enough from past pandemic viruses that they didn’t fall under the Obama administration pause.

Wuhan Institute of Virology and Peter Daszak of EcoHealth Alliance

NIH accepted this argument under the condition that EcoHealth immediately stop its work and notify the agency if any of its hybrid viruses did show increased viral growth in humanized mice.

But when these hybrid viruses did show increased viral growth in mice, EcoHealth did not immediately stop work or notify NIH. It instead waited until it submitted an annual progress report in 2018 to disclose the results of its experiments.

A second progress report that EcoHealth submitted in 2021, two years after its due date, also showed its hybrid viruses were demonstrating increased viral growth and enhanced lethality in humanized mice.

In testimony to the House’s coronavirus subcommittee earlier this month, Daszak claimed that EcoHealth attempted to report the results of its gain-of-function experiments on time in 2019, but was frozen out of NIH’s reporting system.

The HHS memo released today says a forensic investigation found no evidence that EcoHealth was locked out of NIH’s reporting system. The department also said that EcoHealth had failed to produce requested lab notes and other materials from the Wuhan lab detailing the work being done there and the lab’s biosafety conditions.

These all amount to violations of EcoHealth’s grant agreement and NIH grant policy, thus warranting debarment from future federal funds, reads the HHS memo.

That EcoHealth would be stripped of its federal funding shouldn’t come as too great a shock to anyone who watched Daszak’s congressional testimony from earlier this month. Even Democrats on the committee openly accused Daszak of being misleading about EcoHealth’s work and manipulating facts.

Rep. Raul Ruiz (D–Calif.), the ranking Democrat on the House’s coronavirus subcommittee, welcomed EcoHealth’s suspension, saying in a press release that the nonprofit failed its “obligation to meet the utmost standards of transparency and accountability to the American public.”

An HHS Office of the Inspector General report from last year had already found that EcoHealth had failed to submit progress reports on time or effectively monitor its subgrantee, the Wuhan Institute of Virology.

When grilling Daszak, Democrats on the Coronavirus Subcommittee went to great lengths to not criticize NIH’s oversight of EcoHealth’s work. The HHS debarment memo likewise focuses only on EcoHealth’s failures to abide by NIH policy and its grant conditions.

Nevertheless, it seems pretty obvious that NIH was failing to abide by the 2014 pause on gain-of-function funding when it allowed EcoHealth to go ahead with creating hybrid coronaviruses under the condition that they stop if the viruses did prove more virulent.

NIH compounded that oversight failure by not stopping EcoHealth’s funding when the nonprofit did, in fact, create more virulent viruses, and not following up on a never-submitted progress report detailing more gain-of-function research until two years later.

The House Subcommittee’s investigation into NIH’s role in gain-of-function research at the Wuhan lab is ongoing. Tomorrow it will interview NIH Principal Deputy Director Lawerence Tabak. In June, it will interview former NIAID Director Anthony Fauci.

Originally published by Reason Foundation. Republished with permission.

Related Topics:

Todayville is a digital media and technology company. We profile unique stories and events in our community. Register and promote your community event for free.

Follow Author

More from this author
2025 Federal Election / 6 hours ago

The Liberals torched their own agenda just to cling to power

Business / 6 hours ago

Canada urgently needs a watchdog for government waste

Business / 8 hours ago

Trump says he expects ‘great relationship’ with Carney, who ‘hated’ him less than Poilievre

COVID-19

Study finds Pfizer COVID vaccine poses 37% greater mortality risk than Moderna

Published on May 1, 2025

By

From LifeSiteNews

By Nicolas Hulscher, MPH

A study of 1.47 million Florida adults by MIT’s Retsef Levi and Surgeon General Joseph Ladapo finds significantly higher all-cause mortality after Pfizer vaccination compared to Moderna

A new study of 1.47 million Florida adults by MIT’s Retsef Levi and Surgeon General Joseph Ladapo finds significantly higher all-cause, cardiovascular, and COVID-19 mortality after Pfizer vaccination.

The study titled “Twelve-Month All-Cause Mortality after Initial COVID-19 Vaccination with Pfizer-BioNTech or mRNA-1273 among Adults Living in Florida” was just uploaded to the MedRxiv preprint server. This study was headed by MIT Professor Retsef Levi, with Florida Surgeon General Dr. Joseph Ladapo serving as senior author:

Study Overview

  • Population: 1,470,100 noninstitutionalized Florida adults (735,050 Pfizer recipients and 735,050 Moderna recipients).
  • Intervention: Two doses of either:
    • BNT162b2 (Pfizer-BioNTech)
    • mRNA-1273 (Moderna)
  • Follow-up Duration: 12 months after second dose.
  • Comparison: Head-to-head between Pfizer vs. Moderna recipients.
  • Main Outcomes:
    • All-cause mortality
    • Cardiovascular mortality
    • COVID-19 mortality
    • Non-COVID-19 mortality

All-cause mortality

Pfizer recipients had a significantly higher 12-month all-cause death rate than Moderna recipients — about 37% higher risk.

  • Pfizer Risk: 847.2 deaths per 100,000 people
  • Moderna Risk: 617.9 deaths per 100,000 people
  • Risk Difference:
    ➔ +229.2 deaths per 100,000 (Pfizer excess)
  • Risk Ratio (RR):
    ➔ 1.37 (i.e., 37% higher mortality risk with Pfizer)
  • Odds Ratio (Adjusted):
    ➔ 1.384 (95% CI: 1.331–1.439)

Cardiovascular mortality

Pfizer recipients had a 53% higher risk of dying from cardiovascular causes compared to Moderna recipients.

  • Pfizer Risk: 248.7 deaths per 100,000 people
  • Moderna Risk: 162.4 deaths per 100,000 people
  • Risk Difference:
    ➔ +86.3 deaths per 100,000 (Pfizer excess)
  • Risk Ratio (RR):
    ➔ 1.53 (i.e., 53% higher cardiovascular mortality risk)
  • Odds Ratio (Adjusted):
    ➔ 1.540 (95% CI: 1.431–1.657)

COVID-19 mortality

Pfizer recipients had nearly double the risk of COVID-19 death compared to Moderna recipients.

  • Pfizer Risk: 55.5 deaths per 100,000 people
  • Moderna Risk: 29.5 deaths per 100,000 people
  • Risk Difference:
    ➔ +26.0 deaths per 100,000 (Pfizer excess)
  • Risk Ratio (RR):
    ➔ 1.88 (i.e., 88% higher COVID-19 mortality risk)
  • Odds Ratio (Adjusted):
    ➔ 1.882 (95% CI: 1.596–2.220)

Non-COVID-19 mortality

Pfizer recipients faced a 35% higher risk of dying from non-COVID causes compared to Moderna recipients.

  • Pfizer Risk: 791.6 deaths per 100,000 people
  • Moderna Risk: 588.4 deaths per 100,000 people
  • Risk Difference:
    ➔ +203.3 deaths per 100,000 (Pfizer excess)
  • Risk Ratio (RR):
    ➔ 1.35 (i.e., 35% higher non-COVID mortality risk)
  • Odds Ratio (Adjusted):
    ➔ 1.356 (95% CI: 1.303–1.412)

Biological explanations

The findings of this study are surprising, given that Moderna’s mRNA-1273 vaccine contains approximately three times more mRNA (100 µg) than Pfizer’s BNT162b2 vaccine (30 µg). This suggests that the higher mortality observed among Pfizer recipients could potentially be related to higher levels of DNA contamination — an issue that has been consistently reported worldwide:

The paper hypothesizes differences between Pfizer and Moderna may be due to:

  • Different lipid nanoparticle compositions
  • Differences in manufacturing, biodistribution, or storage conditions

Final conclusion

Florida adults who received Pfizer’s BNT162b2 vaccine had higher 12-month risks of all-cause, cardiovascular, COVID-19, and non-COVID-19 mortality compared to Moderna’s mRNA-1273 vaccine recipients.

Unfortunately, without an unvaccinated group, the study cannot determine the absolute increase in mortality risk attributable to mRNA vaccination itself. However, based on the mountain of existing evidence, it is likely that an unvaccinated cohort would have experienced much lower mortality risks. It’s also important to remember that Moderna mRNA injections are still dangerous.

As the authors conclude:

These findings are suggestive of differential non-specific effects of the BNT162b2 and mRNA-1273 COVID-19 vaccines, and potential concerning adverse effects on all-cause and cardiovascular mortality. They underscore the need to evaluate vaccines using clinical endpoints that extend beyond their targeted diseases.

Nicolas Hulscher, MPH

Epidemiologist and Foundation Administrator, McCullough Foundation

www.mcculloughfnd.org

Please consider following both the McCullough Foundation and my personal accounton X (formerly Twitter) for further content.

Reprinted with permission from Focal Points.

Continue Reading

COVID-19

Canada’s health department warns COVID vaccine injury payouts to exceed $75 million budget

Published on April 30, 2025

By

Fr0m LifeSiteNews

By Clare Marie Merkowsky

A Department of Health memo warns that Canada’s Vaccine Injury Support Program will exceed its $75 million budget due to high demand, with $16 million already paid out.

COVID vaccine injury payments are expected to go over budget, according to a Canadian Department of Health memo.

According to information published April 28 by Blacklock’s Reporter, the Department of Health will exceed their projected payouts for COVID vaccine injuries, despite already spending $16 million on compensating those harmed by the once-mandated experimental shots.

“A total $75 million in funding has been earmarked for the first five years of the program and $9 million on an ongoing basis,” the December memo read. “However the overall cost of the program is dependent on the volume of claims and compensation awarded over time, and that the demand remains at very high levels.”

“The purpose of this funding is to ensure people in Canada who experience a serious and permanent injury as a result of receiving a Health Canada authorized vaccine administered in Canada on or after December 8, 2020 have access to a fair and timely financial support mechanism,” it continued.

Canada’s Vaccine Injury Support Program (VISP) was launched in December 2020 after the Canadian government gave vaccine makers a shield from liability regarding COVID-19 jab-related injuries.

While Parliament originally budgeted $75 million, thousands of Canadians have filed claims after received the so-called “safe and effective” COVID shots. Of the 3,060 claims received to date, only 219 had been approved so far, with payouts totaling over $16 million.

Since the start of the COVID crisis, official data shows that the virus has been listed as the cause of death for less than 20 kids in Canada under age 15. This is out of six million children in the age group.

The COVID jabs approved in Canada have also been associated with severe side effects such as blood clots, rashes, miscarriages, and even heart attacks in young, healthy men.

Additionally, a recent study done by researchers with Canada-based Correlation Research in the Public Interest showed that 17 countries have found a “definite causal link” between peaks in all-cause mortality and the fast rollouts of the COVID shots as well as boosters.

Interestingly, while the Department of Health has spent $16 million on injury payouts, the Liberal government spent $54 million COVID propaganda promoting the vaccine to young Canadians.

The Public Health Agency of Canada especially targeted young Canadians ages 18-24 because they “may play down the seriousness of the situation.”

The campaign took place despite the fact that the Liberal government knew about COVID vaccine injuries, according to a secret memo.

Continue Reading

Trending

X